Compare ACADIA Pharmaceuticals Inc. (ACAD) vs State Street Real Estate Select Sector SPDR ETF (XLRE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs State Street Real Estate Select Sector SPDR ETF — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.74 (market cap $4.49B), while State Street Real Estate Select Sector SPDR ETF trades at $44.29. Which is the better fit depends on your goals.
| ACAD | XLRE | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | Sector/Thematic |
52-Week High | $28.06 | $45.36 |
52-Week Low | $20.06 | $40.01 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
XLRE trades at $44.29, down 0.9% on the day, with technical indicators showing a neutral to bearish bias. The ETF maintains a low 0.08% expense ratio and focuses exclusively on U.S. real estate investment trusts. Recent news highlights XLRE's cost advantage over global real estate ETFs and discusses the REIT sector's resilience amid interest rate volatility.
The outlook for XLRE hinges on U.S. real estate fundamentals and interest rate trends. Opportunities include potential sector recovery and durable dividends, but risks remain from rising Treasury yields and economic uncertainty. Wall Street sentiment is mixed, with technicals suggesting near-term consolidation around key support at $44.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About State Street Real Estate Select Sector SPDR ETF
XLRE tracks the Real Estate Select Sector Index, providing exposure to S&P 500 real estate companies. It focuses on equity REITs across residential, industrial, and healthcare sub-sectors, with top holdings like Welltower, Prologis, and American Tower.
Read more on XLRE →
